Company

VITASPRING BIOMEDICAL CO. LTD.

Public · VSBC

VitaSpring Biomedical develops stem cell therapies focused on regenerative medicine, preventive healthcare, cosmetics, and anti-aging treatments. The company isolates and purifies mesenchymal stem cells from placental tissue using proprietary technology and manufactures products in an FDA-compliant GTP laboratory in Irvine, California. VitaSpring's research spans over 15 years and targets applications in regenerative therapy and immune diseases.

VITASPRING BIOMEDICAL CO. LTD. is a publicly traded company. It trades under the ticker VSBC. Leadership tracked by CEOInsider includes Jing-Zhou Chen (CEO).

www.vitaspringbio.com ↗

Leadership

Current

Jing-Zhou Chen

CEO

Recent developments

AI summary of recent coverage

Recent coverage has focused on VitaSpring Biomedical Co. Ltd's regulatory filings and share price activity, alongside leadership changes at the company. The headlines indicate Form 8K filings were submitted in September 2026 and include references to new appointments in executive and board positions.

Summarized from the headlines in the sidebar; see each source for the full story.